All News

Sheng Fu, MD, explains why patients with overlapping cardiac, renal, and metabolic disease demand new care models.

Topical delgocitinib in chronic hand eczema improves clearance and itch fast, with placebo-like safety.

New wastewater data and prior research suggest COVID-19 may follow recurring spring and summer transmission patterns, unlike influenza and RSV.

Senate Democrats introduced a bill to cap out-of-pocket costs at $5000 for traditional Medicare beneficiaries and expand low-income assistance.

Longer sleep is linked to lower glycemic variability and reduced deviation risk in adolescents; higher daytime variability predicted shorter subsequent sleep.

Adam Kittai, MD, reviews AMPLIFY data supporting acalabrutinib-venetoclax (AV) for CLL, citing strong safety and survival outcomes for select patients.

Rrisankizumab is the first and only IL-23 inhibitor FDA-approved for children aged 6 and older under 40 kg with plaque psoriasis or psoriatic arthritis.

Veligrotug-vvze (Lumvoa; Viridian Therapeutics) is the first treatment for thyroid eye disease (TED) that has been approved by the FDA with labeling that includes data for both active and chronic TED.

Summary of Nonconsensus Discussions: Bridging the Gaps in Health Equity & Access in Multiple Myeloma | May 2, 2026, Tampa, Florida

New research reveals complex treatment costs from MM strain patients and caregivers during active therapy, while pain goes undertreated at end of life.

A single-center study found low rates of MRA and SGLT2 inhibitor prescribing among low-income, largely uninsured patients with heart failure.

Lower rates of successful discharge were reported in home health care patients whose care was interrupted by flooding related to hurricanes.

Participants highlight critical gaps in the diagnosis, treatment, and coordination of care for patients with heart failure.

Deloitte's Pete Lyons explains the confidence gap, diverging biopharmaceutical and medical technology risks, and what separates real AI value from activity.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

A population-based study linked male sex, Hispanic ethnicity, and select birth and parental factors to increased EOCRC risk.

A multidisciplinary Philadelphia roundtable surfaced the structural barriers that keep people with AD from reaching effective therapy.

Caregivers of patients with CKD report social withdrawal, strained relationships, and stigma, according to a new qualitative evidence synthesis.

An MRI study found hypothalamic atrophy across most subregions in adults with narcolepsy type 1, with the tuberal-inferior region relatively spared.

Spending on health expenditures will make up 20.6% of gross domestic product, according to a federal report.

Clinicians and pharmacists at Temple and Penn discuss barriers to multidisciplinary obesity care, from ICD-10 coding gaps to prior authorization burdens.

Independent investigations found that venetoclax-based combination regimens achieved high response and strong MRD negativity in newly diagnosed leukemias.

Epcoritamab shows high rates of first-line response and MRD negativity in older patients with chemo-ineligible DLBCL, whether used alone or with R-mini-CHOP.

SEER and Medicare data project rising DLBCL and MCL cases through 2032, intensifying payer strain and demand for Brukinsa, Calquence, and CAR-T access.

ASCO real-world oncology data show racial disparities in pain management, with delayed meds and fewer strong opioids for Black and Asian patients.

Deloitte's midyear analysis shows internal confidence rising even as external uncertainty over policy, tariffs, and reimbursement persists for biopharma and medtech.

FDA approves palbociclib (Ibrance) for HR+, HER2+ metastatic breast cancer maintenance, based on phase 3 PATINA data showing a 24% reduction in progression risk.

Interviews with patients living with generalized myasthenia gravis (MG) in the US revealed areas of increased burden in these patients.